4.2 Article

Extreme elevation of acute phase reactants and shock secondary to dabrafenib-trametinib

Journal

MELANOMA RESEARCH
Volume 31, Issue 3, Pages 268-271

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/CMR.0000000000000733

Keywords

metastatic melanoma; pyrexia; shock; tyrosine-kinase inhibitors

Ask authors/readers for more resources

The emerging role of BRAF and MEK tyrosine-kinase inhibitors provides new treatment opportunities for patients with advanced melanoma and BRAF mutations, but may be associated with toxicities. This case report describes a patient who developed multiple episodes of fever, hypotension, and acute phase reactants elevation while on dabrafenib and trametinib therapy, initially managed as septic shock without evidence of infection. After dose reduction of dabrafenib, the fever episodes resolved.
The emerging role of BRAF and MEK tyrosine-kinase inhibitors has shown new opportunities of treatment for patients with advanced melanoma and BRAF mutations. Its use is associated with some toxicities, as pyrexia, that clinicians may not be familiarized with. We present the case of a patient diagnosed with stage IV melanoma BRAF Val600E mutated who was started on dabrafenib and trametinib and developed three severe episodes of fever, hypotension and acute phase reactants elevation during the first 3 months of therapy, in the absence of microbiological demonstration of infection. The episodes were initially managed as a septic shock with broad-spectrum antibiotics and vasoactive drugs, while treatment with dabrafenib and trametinib was withheld. After two subsequent dose reduction of dabrafenib, the patient did not experience new episodes of fever.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available